Aeglea BioTherapeutics | LinkedIn (original) (raw)

About us

With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD. For more information, please visit http://aeglea.com.

Industry

Biotechnology Research

Company size

51-200 employees

Headquarters

Austin, Texas

Type

Public Company

Founded

2013

Specialties

biotech, biotechnology, rare disease, human enzymes, and engineering enzymes

Locations

Employees at Aeglea BioTherapeutics

Similar pages

Browse jobs

Funding